1.32
+0.09(+7.32%)
Currency In USD
| Previous Close | 1.23 |
| Open | 1.23 |
| Day High | 1.33 |
| Day Low | 1.22 |
| 52-Week High | 4.42 |
| 52-Week Low | 0.85 |
| Volume | 262,978 |
| Average Volume | 636,804 |
| Market Cap | 59.92M |
| PE | -1.28 |
| EPS | -1.03 |
| Moving Average 50 Days | 1.24 |
| Moving Average 200 Days | 2.36 |
| Change | 0.09 |
If you invested $1000 in PDS Biotechnology Corporation (PDSB) since IPO date, it would be worth $6 as of April 25, 2025 at a share price of $1.32. Whereas If you bought $1000 worth of PDS Biotechnology Corporation (PDSB) shares 5 years ago, it would be worth $1,392.41 as of April 25, 2025 at a share price of $1.32.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
PDS Biotech Announces Multiple Abstracts Selected for Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
GlobeNewswire Inc.
Apr 23, 2025 2:16 PM GMT
PRINCETON, N.J., April 23, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today ann
PDS Biotech Announces Preclinical Influenza Data to be Presented in Symposium at IMMUNOLOGY2025™ Annual Meeting
GlobeNewswire Inc.
Apr 16, 2025 12:00 PM GMT
Update on American Association for Cancer Research Annual Meeting 2025 presentationPRINCETON, N.J., April 16, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company
PDS Biotech Announces PDS01ADC Clinical Data to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2025
GlobeNewswire Inc.
Apr 08, 2025 12:00 PM GMT
NCI presentation to highlight IL-12 fused antibody drug conjugate during poster presentation PRINCETON, N.J., April 08, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunothera